The promise of genomic medicine, fulfilled
At Addition Therapeutics, we are building a future where genomic medicines are a safer, durable, and accessible option for patients with both chronic and rare diseases.
-
PRECISE
Precise and accurate insertion improves safety.
-
RNA-mediated
RNA and LNP components are hypoimmune with understood manufacturing and proven delivery.
-
INSERTION OF
Permanent insertion produces durable effect.
-
TRANSGENES
Ability to express any transgene gives broad therapeutic opportunity.
PRINT Platform
The unified PRINT platform simplifies drug development.
Only the genetic sequence in the template RNA varies across PRINTed medicines. All other components remain the same.
With a target site conserved across animal species, surrogate reagents are a thing of the past.
Everyday biology, extraordinary outcomes.
We co-opt a natural, evolutionarily optimized mechanism taking place in our bodies every day -- retrotransposition -- to drive site-specific insertion of therapeutic transgenes. Known as “selfish DNA”, normal retrotransposons excel at copying themselves. The key innovation behind PRINT is re-educating them to be selfless instead.
Once released into the cytoplasm, one PRINT RNA is translated to make a retrotransposase; the other is bound by this enzyme and destined to become the inserted transgene. Only this RNA is bound by the retrotransposase because only this RNA contains a special sequence - transplanted from the normal retrotransposase RNA - that marks it as a PRINT substrate, breaking the cycle of selfishness. After safe insertion, the transgene goes to work, driving durable protein expression and therapeutic effect - and bringing the promise of genomic medicines to life.
